Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
While pneumococcal conjugate vaccines have shown to be highly effective against invasive pneumococcal disease, their potential effectiveness against acute otitis media (AOM) might become a major economic driver for implementing these vaccines in national immunization programmes. However, the relationship between the costs and benefits of available vaccines remains a controversial topic. Our objective is to systematically review the literature on the cost effectiveness of pneumococcal conjugate vaccination against AOM in children. We searched PubMed, Cochrane and the Centre for Reviews and Dissemination databases (Database of Abstracts of Reviews of Effects [DARE], NHS Economic Evaluation Database [NHS EED] and Health Technology Assessment database [HTA]) from inception until 18 February 2010. We used the following keywords with their synonyms: 'otitis media', 'children', 'cost-effectiveness', 'costs' and 'vaccine'. Costs per AOM episode averted were calculated based on the information in this literature. A total of 21 studies evaluating the cost effectiveness of pneumococcal conjugate vaccines were included. The quality of the included studies was moderate to good. The cost per AOM episode averted varied from &U20AC;168 to &U20AC;4214, and assumed incidence rates varied from 20,952 to 118,000 per 100,000 children aged 0-10 years. Assumptions regarding direct and indirect costs varied between studies. The assumed vaccine efficacy of the 7-valent pneumococcal CRM197-conjugate vaccine was mainly adopted from two trials, which reported 6-8% efficacy. However, some studies assumed additional effects such as herd immunity or only took into account AOM episodes caused by serotypes included in the vaccine, which resulted in efficacy rates varying from 12% to 57%. Costs per AOM episode averted were inversely related to the assumed incidence rates of AOM and to the estimated costs per AOM episode. The median costs per AOM episode averted tended to be lower in industry-sponsored studies. Key assumptions regarding the incidence and costs of AOM episodes have major implications for the estimated cost effectiveness of pneumococcal conjugate vaccination against AOM. Uniform methods for estimating direct and indirect costs of AOM should be agreed upon to reliably compare the cost effectiveness of available and future pneumococcal vaccines against AOM.
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands.
Chantal W B
CW
Boonacker
Pieter H
PH
Broos
Elisabeth A M
EA
Sanders
Anne G M
AG
Schilder
Maroeska M
MM
Rovers
D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D010033:Otitis Media / Q000191:economics* / Q000517:prevention & control; D011008:Pneumococcal Infections / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000191:economics*; D013296:Streptococcus pneumoniae / Q000276:immunology; D014611:Vaccination / Q000191:economics*; D018074:Vaccines, Conjugate / Q000191:economics
D022242:Pneumococcal Vaccines; D018074:Vaccines, Conjugate
Scand J Infect Dis. 2005;37(11-12):821-32
16308215
Vaccine. 2005 Mar 18;23(17-18):2342-8
15755625
Int J Pediatr Otorhinolaryngol. 2005 Aug;69(8):1031-41
16005345
Vaccine. 2003 Jul 4;21(23):3273-81
12804858
Otolaryngol Head Neck Surg. 1996 Apr;114(4):525-30
8643261
Am J Otolaryngol. 1986 Jan-Feb;7(1):47-54
3953969
Vaccine. 2003 Jun 2;21(19-20):2564-72
12744892
Pediatrics. 2009 Jun;123(6):1452-63
19482754
J Infect Dis. 1989 Jul;160(1):83-94
2732519
Curr Opin Otolaryngol Head Neck Surg. 2004 Dec;12(6):488-94
15548905
Pediatrics. 2000 Jun;105(6):E72
10835085
Clin Vaccine Immunol. 2010 May;17(5):840-7
20219881
Clin Ther. 2009 Oct;31(10):2152-69
19922887
N Engl J Med. 2001 Feb 8;344(6):403-9
11172176
Clin Ther. 2003 Oct;25(10):2614-30
14667962
An Pediatr (Barc). 2004 Feb;60(2):125-32
14757015
BMJ. 1996 Aug 3;313(7052):275-83
8704542
An Esp Pediatr. 1996 May;44(5):433-6
8928965
Pediatr Infect Dis J. 2010 Apr;29(4):304-9
19935445
Vaccine. 2009 Nov 5;27(47):6483-94
19720366
Vital Health Stat 10. 1991 Oct;(180):1-22
1746160
Epidemiol Infect. 1998 Dec;121(3):529-34
10030701
Methods Inf Med. 1999 Dec;38(4-5):339-44
10805025
Health Econ. 2001 Dec;10(8):751-74
11747055
Euro Surveill. 2009 Mar 26;14(12):
19341605
Pediatr Infect Dis J. 2000 Mar;19(3):187-95
10749457
Vaccine. 2010 Mar 8;28(11):2302-10
20064478
Pediatrics. 2006 Sep;118(3):865-73
16950975
J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45
20044845
Vaccine. 2009 Mar 4;27(10):1601-8
19146905
Clin Infect Dis. 1999 Jul;29(1):155-60
10433579
JAMA. 2000 Mar 15;283(11):1460-8
10732936
Eur J Health Econ. 2008 Feb;9(1):7-15
17333089
Rev Panam Salud Publica. 2009 Dec;26(6):518-28
20107706
Pharmacoeconomics. 2003;21(8):587-600
12751916
Clin Infect Dis. 2003 Feb 1;36(3):259-68
12539065
Can J Infect Dis. 2003 Jul;14(4):215-20
18159460
Pharmacoeconomics. 2006;24(2):141-53
16460135
Vaccine. 2006 Jul 17;24(29-30):5690-9
16735083
Lancet. 2006 Mar 4;367(9512):740-8
16517274
Scand J Infect Dis. 2008;40(9):721-9
18712627
Pediatr Infect Dis J. 2007 Oct;26(10 Suppl):S12-6
18049375
Vaccine. 2004 Mar 12;22(9-10):1138-49
15003641
Lancet. 2004 Feb 7;363(9407):465-73
14962529
Value Health. 2004 Jan-Feb;7(1):36-51
14720129